In Section A, members will acquire different doses and schedules of oral ABBV-744 tablet to recognize Harmless dosing regimen. Added contributors will probably be enrolled for the identified monotherapy dosign regimen. In Segment B, individuals will receive oral ruxolitinib and ABBV-744 is going to be given as "include-on" therapy. In https://abbv-744brd4inhibitioninc91357.newbigblog.com/38161411/considerations-to-know-about-is-abbv-744-effective-for-hematologic-cancers